linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Pharma

Japan’s AnGes preps capacity for 1 million doses as vaccine development continues

The country hopes to counter any second wave of infections by building production capacity while vaccines are still in the works. AnGes is developing a DNA vaccine that will use genetic material from the coronavirus to stimulate the production of human antibodies against the disease. The vaccine is expected to begin clinical trials soon.
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
23 Jun 2020 2 Mins Read 3 comments
A member of Blue Sky Rescue, a humanitarian NGO, puts on a protective suit before fumigating a residential compound in Beijing to prevent coronavirus infection. Getty Images
A member of Blue Sky Rescue, a humanitarian NGO, puts on a protective suit before fumigating a residential compound in Beijing to prevent coronavirus infection.
A team led by Japanese biotech venture AnGes, Inc. will ready production capacity for 1 million doses of coronavirus vaccines by March, a fivefold increase from the original plan, in order to ensure swift access to the domestic population. As top pharmaceutical companies in the U.S. and elsewhere rush to set up facilities capable of producing billions of doses
estimated between 10 billion yen to 20 billion yen. Daiichi Sankyo has partnered with the University of Tokyo to develop a vaccine as well. The Canadian subsidiary of Mitsubishi Tanabe Pharma Corp. plans to begin clinical trials on its vaccine in August. ( This story was originally published by the Nikkei Asian Review.) ( Source: Caixin Global)
A team led by Japanese biotech venture AnGes, Inc. will ready production capacity for 1 million doses of coronavirus vaccines by March, a fivefold increase from the original plan, in order to ensure swift access to the domestic population. As top pharmaceutical companies in the U.S. and elsewhere rush to set up facilities capable of producing billions of doses estimated between 10 billion yen to 20 billion yen. Daiichi Sankyo has partnered with the University of Tokyo to develop a vaccine as well. The Canadian subsidiary of Mitsubishi Tanabe Pharma Corp. plans to begin clinical trials on its vaccine in August. ( This story was originally published by the Nikkei Asian Review.) ( Source: Caixin Global)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

CONTRIBUTORS WHO HAVE COMMENTED ON THIS STORY

test

user Piyush

test

user Manas Vr

test

user Niket shah

Current Edition

Message from Planet Labs’ eye in the sky: India is a medieval knight in the age of modern warfare
Space

Message from Planet Labs’ eye in the sky: India is a medieval knight in the age of modern warfare

Satellite pictures of the Galwan valley region shared by US-based Planet Labs exposed China backtracking on the agreement with India to disengage. While the images did help India foster its case in shaping global opinion, it also exposes the country’s unpreparedness in advanced technologies. The episode underlines the urgent need to nurture companies in satellite imaging and space technology.

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]